E
Edward M Vital
Researcher at University of Leeds
Publications - 131
Citations - 5499
Edward M Vital is an academic researcher from University of Leeds. The author has contributed to research in topics: Rituximab & Medicine. The author has an hindex of 28, co-authored 100 publications receiving 3422 citations. Previous affiliations of Edward M Vital include Leeds Teaching Hospitals NHS Trust & Chapel Allerton Hospital.
Papers
More filters
Journal ArticleDOI
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer,Karen H. Costenbader,David I. Daikh,Ralph Brinks,Marta Mosca,Rosalind Ramsey-Goldman,Josef S Smolen,David Wofsy,Dimitrios T. Boumpas,Diane L. Kamen,David Jayne,Ricard Cervera,Nathalie Costedoat-Chalumeau,Betty Diamond,Dafna D. Gladman,Bevra H. Hahn,Falk Hiepe,Søren Jacobsen,Dinesh Khanna,Kirsten Lerstrøm,Elena Massarotti,Joseph M. McCune,Guillermo Ruiz-Irastorza,Jorge Sanchez-Guerrero,Matthias Schneider,Murray B. Urowitz,George Bertsias,Bimba F. Hoyer,Nicolai Leuchten,Chiara Tani,Sara K. Tedeschi,Zahi Touma,Gabriela Schmajuk,Branimir Anić,Florence Assan,Tak Mao Chan,Ann E. Clarke,Mary K. Crow,László Czirják,Andrea Doria,Winfried Graninger,Bernadett Halda-Kiss,Sarfaraz Hasni,Peter M. Izmirly,Michelle Jung,Gábor Kumánovics,Xavier Mariette,Ivan Padjen,José M. Pego-Reigosa,Juanita Romero-Diaz,Íñigo Rúa-Figueroa Fernández,Raphaèle Seror,Georg Stummvoll,Yoshiya Tanaka,Maria G Tektonidou,Carlos Vasconcelos,Edward M Vital,Daniel J. Wallace,Sule Yavuz,Pier Luigi Meroni,Marvin J. Fritzler,Ray Naden,Thomas Dörner,Sindhu R. Johnson +63 more
TL;DR: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism and the American College of Rheumatology (ACR).
Journal ArticleDOI
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Martin Aringer,Karen H. Costenbader,David I. Daikh,Ralph Brinks,Marta Mosca,Rosalind Ramsey-Goldman,Josef S Smolen,David Wofsy,Dimitrios T. Boumpas,Dimitrios T. Boumpas,Diane L. Kamen,David Jayne,Ricard Cervera,Nathalie Costedoat-Chalumeau,Betty Diamond,Dafna D. Gladman,Bevra H. Hahn,Falk Hiepe,Søren Jacobsen,Dinesh Khanna,Kirsten Lerstrøm,Elena Massarotti,Joseph M. McCune,Guillermo Ruiz-Irastorza,Jorge Sanchez-Guerrero,Matthias Schneider,Murray B. Urowitz,George Bertsias,Bimba F. Hoyer,Nicolai Leuchten,Chiara Tani,Sara K. Tedeschi,Zahi Touma,Gabriela Schmajuk,Branimir Anić,Florence Assan,Tak Mao Chan,Ann E. Clarke,Mary K. Crow,László Czirják,Andrea Doria,Winfried Graninger,Bernadett Halda-Kiss,Sarfaraz Hasni,Peter M. Izmirly,Michelle Jung,Gábor Kumánovics,Xavier Mariette,Ivan Padjen,José M. Pego-Reigosa,Juanita Romero-Diaz,Íñigo Rúa-Figueroa Fernández,Raphaèle Seror,Georg Stummvoll,Yoshiya Tanaka,Maria G Tektonidou,Carlos Vasconcelos,Edward M Vital,Edward M Vital,Daniel J. Wallace,Sule Yavuz,Pier Luigi Meroni,Marvin J. Fritzler,Ray Naden,Thomas Dörner,Sindhu R. Johnson,Sindhu R. Johnson +66 more
TL;DR: These new classification criteria for systemic lupus erythematosus have excellent sensitivity and specificity, and were developed using rigorous methodology with multidisciplinary and international input.
Journal ArticleDOI
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
Shouvik Dass,Simon J. Bowman,Edward M Vital,Kei Ikeda,Colin T. Pease,John Hamburger,Andrea Richards,Saaeha Rauz,Paul Emery +8 more
TL;DR: This is the first double blind, placebo-controlled, randomised pilot study of the efficacy of rituximab in reducing fatigue in Primary Sjögren syndrome to show benefit.
Journal ArticleDOI
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
Abdulla Watad,Gabriele De Marco,Hussein Mahajna,Hussein Mahajna,Amit Druyan,Amit Druyan,Mailam Eltity,Nizar Hijazi,A. Haddad,Muna Elias,Devy Zisman,Mohammad E. Naffaa,Michal Brodavka,Michal Brodavka,Yael Cohen,Yael Cohen,Arsalan Abu-Much,Muhanad Abu Elhija,Charlie Bridgewood,Pnina Langevitz,Pnina Langevitz,Joanna McLorinan,Nicola Luigi Bragazzi,Helena Marzo-Ortega,Merav Lidar,Merav Lidar,Cassandra Calabrese,Leonard H. Calabrese,Edward M Vital,Yehuda Shoenfeld,Yehuda Shoenfeld,Howard Amital,Howard Amital,Dennis McGonagle +33 more
TL;DR: In this paper, the authors evaluated 28 cases of immune-mediated disease flare or new disease onset within 28-days of SARS-CoV-2 vaccination at five large tertiary centres in countries with early vaccination adoption, three in Israel, one in UK, and one in USA.
Journal ArticleDOI
Development of psoriasis after B cell depletion with rituximab
TL;DR: Patients who developed psoriasis after receiving rituximab for a variety of indications, namely, seropositive and seronegative rheumatoid arthritis and systemic lupus erythematosus are described.